Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Brolucizumab—early experience with early extended interval regime in chronic centre involved diabetic macular oedema

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Change in BVCA.
Fig. 2: Change in CST.
Fig. 3: Representative Example.

References

  1. 1.

    Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 2020;127:72–84.

    Article  Google Scholar 

  2. 2.

    Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept. https://www.novartis.com/news/media-releases/novartis-phase-iii-beovu-data-show-potential-fluid-resolution-more-diabetic-macular-edema-patients-fewer-injections-versus-aflibercept. Accessed Aug 2021

  3. 3.

    Sharma A, Kumar N, Parachuri N, Sadda SR, Corradetti G, Heier J, et al. Brolucizumab-early real-world experience: BREW study. Eye. 2021;35:1045–7.

    Article  Google Scholar 

  4. 4.

    Bulirsch LM, Saßmannshausen M, Nadal J, Liegl R, Thiele S, Holz FG. Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study. Br J Ophthalmol. 2021. bjophthalmol-2020-318672.

  5. 5.

    Enríquez AB, Baumal CR, Crane AM, Witkin AJ, Lally DR, Liang MC, et al. Early experience with brolucizumab treatment of neovascular age-related macular degeneration. JAMA Ophthalmol. 2021;139:441–8.

    Article  Google Scholar 

  6. 6.

    Sharma A, Kumar N, Parachuri N, Singh S, Bandello F, Regillo CD, et al. Understanding retinal vasculitis associated with brolucizumab: complex pathophysiology or occam’s razor? Ocul Immunol Inflamm. 2021.

  7. 7.

    Iyer PG, Peden MC, Suñer IJ, Patel N, Dubovy SR, Albini TA. Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: a clinicopathologic case study. Am J Ophthalmol Case Rep. 2020;20:100989 https://doi.org/10.1016/j.ajoc.2020.100989.

    Article  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Sharma A, Kumar N, Parachuri N, Sharma R, Bandello F, Kuppermann BD, et al. Brolucizumab and immunogenicity. Eye. 2020;34:1726–8.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Contributions

AS: conception, analysis, drafting, integrity check, final approval. DC, SM, NP and NK: drafting, analysis, integrity check.

Corresponding author

Correspondence to Ashish Sharma.

Ethics declarations

Competing interests

DC: CONSULTANT: for Novartis, Bayer, Intas. AS: CONSULTANT: for Novartis, Allergan, Bayer, Intas and Lupin. The remaining authors declared no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chakraborty, D., Mondal, S., Parachuri, N. et al. Brolucizumab—early experience with early extended interval regime in chronic centre involved diabetic macular oedema. Eye (2021). https://doi.org/10.1038/s41433-021-01816-3

Download citation

Search

Quick links